Getfast Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 15-12-2024
- Paid Up Capital ₹ 0.10 M
as on 15-12-2024
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -16.11%
(FY 2022)
- Profit -19.77%
(FY 2022)
- Ebitda -18.66%
(FY 2022)
- Net Worth 13.78%
(FY 2022)
- Total Assets 25.07%
(FY 2022)
About Getfast Pharmaceuticals
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Tharahunase Gopinatha and Kusugolli Vivekananda serve as directors at the Company.
- CIN/LLPIN
U85110KA2015PTC081715
- Company No.
081715
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Getfast Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tharahunase Gopinatha  | Director | 21-Sep-2021 | Current |
| Kusugolli Vivekananda | Director | 23-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Getfast Pharmaceuticals.
Getfast Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 16.11% decrease. The company also saw a substantial fall in profitability, with a 19.77% decrease in profit. The company's net worth Soared by an impressive increase of 13.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Getfast Pharmaceuticals?
In 2022, Getfast Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Avantgarde Solutions Private LimitedActive 16 years 9 monthsKusugolli Vivekananda is a mutual person
Pra Ai Technologies Private LimitedActive 1 year 2 monthsTharahunase Gopinatha and Kusugolli Vivekananda are mutual person
- Jeevan Homepharma Private LimitedActive 10 years 5 months
Tharahunase Gopinatha and Kusugolli Vivekananda are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Getfast Pharmaceuticals?
Getfast Pharmaceuticals has a workforce of 30 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Getfast Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Getfast Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
